- Home
- WHF vs MIST Comparison
WHF vs MIST Comparison
Compare WHF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- MIST
- Stock Information
- Founded
- WHF 2011
- MIST 2003
- Country
- WHF United States
- MIST Canada
- Employees
- WHF N/A
- MIST N/A
- Industry
- WHF Finance Companies
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- MIST Health Care
- Exchange
- WHF Nasdaq
- MIST Nasdaq
- Market Cap
- WHF 162.2M
- MIST 164.9M
- IPO Year
- WHF 2012
- MIST N/A
- Fundamental
- Price
- WHF $7.09
- MIST $1.92
- Analyst Decision
- WHF Hold
- MIST Strong Buy
- Analyst Count
- WHF 4
- MIST 3
- Target Price
- WHF $9.17
- MIST $6.33
- AVG Volume (30 Days)
- WHF 153.0K
- MIST 1.5M
- Earning Date
- WHF 11-10-2025
- MIST 11-11-2025
- Dividend Yield
- WHF 25.36%
- MIST N/A
- EPS Growth
- WHF N/A
- MIST N/A
- EPS
- WHF 0.15
- MIST N/A
- Revenue
- WHF $81,499,000.00
- MIST N/A
- Revenue This Year
- WHF N/A
- MIST N/A
- Revenue Next Year
- WHF N/A
- MIST N/A
- P/E Ratio
- WHF $46.00
- MIST N/A
- Revenue Growth
- WHF N/A
- MIST N/A
- 52 Week Low
- WHF $6.53
- MIST $0.63
- 52 Week High
- WHF $12.18
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- WHF 44.48
- MIST 49.45
- Support Level
- WHF $6.96
- MIST $1.85
- Resistance Level
- WHF $7.20
- MIST $2.14
- Average True Range (ATR)
- WHF 0.21
- MIST 0.10
- MACD
- WHF 0.09
- MIST -0.02
- Stochastic Oscillator
- WHF 76.39
- MIST 33.64
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).